✦ LIBER ✦

Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study

✍ Scribed by Libri, Vincenzo; Yandim, Cihangir; Athanasopoulos, Stavros; Loyse, Naomi; Natisvili, Theona; Law, Pui Pik; Chan, Ping Kei; Mohammad, Tariq; Mauri, Marta; Tam, Kin Tung; Leiper, James; Piper, Sophie; Ramesh, Aravind; Parkinson, Michael H; Huson, Les; Giunti, Paola; Festenstein, Richard

Book ID: 122540312
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 502 KB
Volume: 384
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(14)60382-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose escalation of ibandronate in patien

Dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease – an open label study

✍ D. Henrich; R. Bergner; M. Hoffmann; M. Uppenkamp 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 52 KB

P.2.e.022 Effectiveness and safety of am

P.2.e.022 Effectiveness and safety of amisulpride's high dose in acute mania: an open label study

✍ S. Arques; M.A. Pino; D. Villavicencio; P. Sierra; L. Livianos 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Abstract #13: Low-Dose Naltrexone's Tole

Abstract #13: Low-Dose Naltrexone's Tolerability and Effects in Fatigued Patients with Parkinson's Disease: An Open-Label Study

✍ Thomas Guttuso Jr.; Naomi Salins; David Lichter 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 79 KB

An Open-Label, Multi-Dose Efficacy and S

An Open-Label, Multi-Dose Efficacy and Safety Study of Intramuscular Tetrodotoxin in Patients with Severe Cancer-Related Pain

✍ Neil A. Hagen; Kim M. Fisher; Bernard Lapointe; Patrick du Souich; Srini Chary; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 323 KB

A baseline-controlled, open-label, flexi

A baseline-controlled, open-label, flexible dose-escalation study to assess the safety and efficacy of sildenafil citrate (Viagra®) in patients with erectile dysfunction

✍ Benchekroun, A; Faik, M; Benjelloun, S; Bennani, S; El Mrini, M; Smires, A 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 105 KB

Activity and safety of ODM-201 in patien

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

✍ Fizazi, Karim; Massard, Christophe; Bono, Petri; Jones, Robert; Kataja, Vesa; Ja 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 465 KB